U.S. pharma executives expect deals to pick up after tax overhaul

SAN FRANCISCO (Reuters) – The Trump administration’s tax overhaul should accelerate major acquisitions by drugmakers in 2018 after a slow year for deals in 2017, according to senior executives from some of the largest pharmaceutical manufacturers.


Source: Reuters

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>